|   | 
										시장보고서
									 
											
												상품코드
											
										 
											1663812
										 당뇨병망막증 시장 규모, 점유율, 성장 분석 : 유형별, 치료법별, 진단별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)Diabetic Retinopathy Market Size, Share, and Growth Analysis, By Type, By Treatment, By Diagnosis, By Route of Administration, By End-Users, By Distribution Channel, By Region - Industry Forecast 2025-2032 | ||||||
당뇨병망막증 시장 규모는 2023년에 95억 달러로 평가되며, 2024년 101억 6,000만 달러에서 2032년에는 173억 2,000만 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 6.9%로 성장할 전망입니다.
당뇨병 시장은 당뇨병 유병률 증가, 인구 고령화, 당뇨병 관련 실명 발생률 증가 등을 배경으로 크게 성장할 것으로 예상됩니다. 당뇨병에 대한 인식 증가와 혁신적인 제품의 도입이 이러한 추세를 더욱 가속화하고 있습니다. 당뇨병은 췌장의 인슐린 분비 장애로 인해 혈당이 상승하고 망막 모세혈관에 잠재적인 손상을 일으켜 당뇨병성 망막증으로 이어집니다. 이러한 위험을 줄이기 위해서는 조기 발견과 개입, 첨단 툴을 이용한 지속적인 자가 모니터링, 생활습관 개선이 매우 중요합니다. Check Eye의 AI 기반 당뇨망막병증 검진 플랫폼과 같은 최근 구상은 조기 발견을 강화하기 위한 노력을 강조하고 있습니다. 또한 2050년까지 노인 인구가 3배로 증가할 것으로 예상되는 가운데 의료비 지출 증가는 시장 역학을 형성하는 데 필수적인 요소입니다.
Diabetic Retinopathy Market size was valued at USD 9.5 billion in 2023 and is poised to grow from USD 10.16 billion in 2024 to USD 17.32 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).
The diabetes market is poised for significant growth, driven by the escalating prevalence of diabetes, an aging population, and the increasing incidence of diabetes-related blindness. Heightened awareness about diabetes and the introduction of innovative products are further accelerating this trend. The condition arises from the pancreas's inability to produce insulin, leading to elevated blood sugar levels and potential damage to retinal blood capillaries, resulting in diabetic retinopathy. Early identification and intervention, continuous self-monitoring using advanced tools, and lifestyle changes are crucial for mitigating these risks. Recent initiatives, such as Check Eye's AI-powered platform for diabetic retinopathy screening, underscore efforts to enhance early detection. Additionally, rising healthcare spending and the projected tripling of the elderly population by 2050 will be vital in shaping market dynamics.
Top-down and bottom-up approaches were used to estimate and validate the size of the Diabetic Retinopathy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Diabetic Retinopathy Market Segments Analysis
Global Diabetic Retinopathy Market is segmented by Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel and region. Based on Type, the market is segmented into Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy. Based on Treatment, the market is segmented into Medication, Through Device, Surgery and Others. Based on Diagnosis, the market is segmented into Fluorescein Angiography, Optical Coherence Tomography and Others. Based on Route of Administration, the market is segmented into Oral, Intravitreal Injections, Intravitreal Implants, Topical Eye Drops, Laser Surgery, Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Diabetic Retinopathy Market
The diabetic retinopathy market is primarily driven by the rising global incidence of diabetes, which significantly heightens the prevalence of this common complication among diabetic patients. As more individuals are diagnosed with diabetes, the need for effective diagnostic tools and treatment solutions for diabetic retinopathy intensifies. This escalating diabetic population not only underscores the necessity for innovative therapies but also creates an expanding market for specialists and healthcare providers focused on managing and addressing the visual impairments associated with this condition. Consequently, the urgent demand for effective interventions stands as a vital propellant for the growth of the diabetic retinopathy market.
Restraints in the Diabetic Retinopathy Market
The diabetic retinopathy market faces several challenges that hinder its growth. A significant issue is the insufficient awareness among diabetic patients regarding the condition and the critical need for routine eye check-ups. Many individuals remain unaware of the risks associated with diabetic retinopathy, which can lead to severe vision impairment if not addressed promptly. Additionally, access to eye care services is often limited in remote or underserved regions, creating barriers to early detection and timely treatment. These factors collectively restrict the market's potential, underscoring the need for increased education and improved healthcare accessibility to mitigate these restraints.
Market Trends of the Diabetic Retinopathy Market
The diabetic retinopathy market is witnessing a notable trend towards early detection and intervention, driven by an increasing acknowledgment of the condition's progressive nature. Healthcare providers are investing in regular screening programs and community awareness campaigns to educate patients about the importance of timely diagnosis. Concurrently, advancements in imaging technologies, such as OCT and fundus photography, are enhancing the precision of early diagnosis. This proactive approach not only aims to reduce the incidence of severe vision loss but also to optimize treatment outcomes, thereby shaping the market dynamics and stimulating growth as both healthcare systems and patients prioritize preventive strategies.